ASH Clinical News October 2017 | Page 40

HELP TAKE YOUR PATIENTS WITH ADULT CHRONIC IMMUNE THROMBOCY TOPENIA FROM REPEATED RELAPSE TO LONG-TERM RESPONSE Indication PROMACTA is indicated for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Limitation of Use PROMACTA should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. Important Safety Information for PROMACTA ® (eltrombopag) WARNING: RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C In patients with chronic hepatitis C, PROMACTA in combination with interferon and ribavirin may increase the risk of hepatic decompensation. (See Section 5.1 of the full Prescribing Information for additional information). RISK OF HEPATOTOXICITY PROMACTA may increase the risk of severe and potentially life-threatening hepatotoxicity. Monitor hepatic function and discontinue dosing as recommended. (See Section 5.2 of the full Prescribing Information for additional information).